MIEBO is the First and Only Prescription Eye Drop that Directly Targets Tear Evaporation, the Leading Cause of Dry Eye DiseaseVAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to
OVERLAND PARK, Kan.--(BUSINESS WIRE)--Compass Minerals (NYSE: CMP), a leading global provider of essential minerals, today announced that it will participate virtually in CL King’s 21st Annual Best Ideas Conference on Sept. 18, 2023. Lorin Crenshaw, chi
Entertainment offerings dominate with television, music and gaming leading subscriptions purchasedTORONTO--(BUSINESS WIRE)--Subscription services are available for almost anything – from everyday things like television and clothing to more niche offeri
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia--(BUSINESS WIRE)--Mednow Inc. (TSXV: MNOW) (OTCQX: MDNWF) ("Mednow" or the "Company"), Canada’s on-demand virtual pharmacy, is pleased to an
TORONTO--(BUSINESS WIRE)--$ATBPF--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its a
The Company to host an earnings conference call via webcastVICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today
TORONTO--(BUSINESS WIRE)--Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce the appointment of Lucie Letellier to the role of Chief Financial Officer effective September 11, 20
Israel’s largest cannabis facility taps into REMY and Fluence’s LED technology for better control over its cultivation process, leading to higher consistency throughout the growAUSTIN, Texas & ROTTERDAM, Netherlands--(BUSINESS WIRE)--Fluence, a leadi
Multi-center, randomized, controlled, open-label study to enroll up to 60 patients with first recurrent GBM FDA has granted both Fast Track Designation and Orphan Drug Designation to VBI-1901 in the recurrent setting, following encouraging Phase 1/2a s
The acquisition points up the Group’s ambition to provide its clinical research customers with best-in-class scientific input and critical flexibility for their drug development programs. It will reinforce Pharmacokinetic / Pharmacodynamic (PKPD) and
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.